首页 赛诺菲-安万特(usSNY)-基本信息

赛诺菲-安万特(usSNY)-基本信息

日报更新时间:04-22 10:30

周报更新时间:04-18 04:06

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

中文名称:赛诺菲-安万特


英文名称:Sanofi SA


行业:医疗


简介:Sanofi是一家全球医疗保健公司,专注于病人的需要并从事研究,开发,制造和销售医疗产品


电话:33-1-53774000


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 持股信息
  • 领导人信息

赛诺菲-安万特,由赛诺菲-圣德拉堡和安万特两家公司在2004年合并成立。2004年年初,赛诺菲欲通过恶意收购的方式在股市并购市值被严重低估的安万特公司。开始提出的并购方案为:公司名称保持赛诺菲原名,而新公司董事会全部由赛诺菲董事会成员构成。由于并购方案本身的不合理性,此收购开始受到安万特公司的坚决抵制,其他公司如诺华(Novatis)也有意介入充当白骑士。由于两家公司均将总部设于法国境内,该收购案受到了法国政府的密切关注,最终在法国政府的干预下,达成和解。并购后双方各占50%的董事会席位。赛诺菲通过资本运作和政府公关成功收购了比自己组织机构更为庞大的公司,这一收购已经成为并购案中的典型案例。法国赛诺菲-安万特集团(Sanofi-Aventis)是欧洲排名第一,全球第四大的药厂(仅次于辉瑞、强生和葛兰素史克,高于默克和阿斯利康制药)。赛诺菲集团在七大治疗领域居领先地位:心血管疾病、血栓形成、肿瘤学、糖尿病、中枢神经系统、内科学和疫苗。赛诺菲在疫苗领域的地位与GSK相当而在抗癌药物研发方面与诺华相当,是一家当之无愧的世界生物制药龙头企业。2018年1月29日,赛诺菲同意以116亿美元收购美国血友病药物生产商Bioverativ,为其七年来规模最大的一笔交易。赛诺菲集团未来专注的7大领域:赛诺菲中国(摘自官网):1982年,赛诺菲进入中国市场。经过30多年的发展,赛诺菲目前在中国拥有7000余名员工,是国内增长最快的医药健康企业之一。赛诺菲在中国的总部位于上海,并在北京、天津、沈阳、济南、上海、杭州、南京、武汉、成都、广州和乌鲁木齐共设11家区域办公室。 处方药 赛诺菲在心血管疾病、糖尿病、肿瘤、中枢神经系统疾病、内科疾病和生物外科等领域拥有创新的产品,专注患者需求,全方位满足中国公共卫生需求。 疫苗 赛诺菲旗下疫苗事业部赛诺菲巴斯德是世界领先的疫苗生产企业。赛诺菲巴斯德在预防流感、肺炎和儿童疾病等领域拥有创新的疫苗产品,积极参与并推进中国预防免疫事业的发展。 健康药业 2010年10月,赛诺菲与民生药业集团共同组建杭州赛诺菲民生健康药业有限公司,赛诺菲在合资公司中占多数股权。2011年2月,赛诺菲完成了对BMP太阳石的收购,一举成为中国领先的健康药业企业,并在维生素矿物质补充品和感冒咳嗽两大健康药业细分市场中占据强势地位。 罕见病 健赞(Genzyme)是世界领先的生物科技公司之一,也是全球罕见病领域的领导者。2011年,健赞成为赛诺菲集团旗下的子公司。 健赞在中国通过连续13年的慈善援助帮助131位戈谢氏病人获得新生,并自2006年起通过积极推进罕见病政策来提高中国罕见病患者的药物可及性,矢志不渝地推进中国罕见病事业的发展。 动物保健 梅里亚(Merial)是赛诺菲集团的动物保健部,领先全球动物保健行业。梅里亚目前在中国拥有三家合资企业和一家贸易公司,主要生产和销售家禽疫苗产品,用于防治感染肉鸡和蛋鸡的各种疾病,并提供相关的免疫器械与免疫配套服务。同时,梅里亚的猪和宠物的进口疫苗和化药产品也是国内兽医师和专业人士广为推荐的品牌。

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Hamlin Capital Management, LLC 1887499 0.08% -90078 -4.55% 2019-03-31
Invesco Advisers, Inc. 5091359 0.20% -- -- 2019-07-31
Fidelity Management & Research Company 5436980 0.22% 306 0.01% 2019-07-31
Fidelity Management and Research Company 8490358 0.34% 95080 1.13% 2019-03-31
FMR Inc 9233558 0.37% 175580 1.94% 2019-03-31
Vanguard 12106718 0.48% -590800 -4.65% 2019-07-31
Fisher Asset Management, LLC 16500462 0.66% 459410 2.86% 2019-03-31
Barrow Hanley Mewhinney & Strauss LLC 22577280 0.90% 110258 0.49% 2019-03-31
Dodge & Cox 60590539 2.43% 214367 0.36% 2019-03-31
Bank of America Corporation 4264945 0.17% 468833 12.35% 2019-03-31
Macquarie Group Ltd 3259967 0.13% 96849 3.06% 2019-03-31
Hotchkis & Wiley Capital Management LLC 3241432 0.13% -1634458 -33.52% 2019-03-31
Olive Street Investment Advisers, LLC 1956378 0.08% -107205 -5.20% 2019-07-31
PRIMECAP Management Company 1955700 0.08% -- -- 2019-03-31
Parametric Portfolio Associates LLC 2047006 0.08% -2619 -0.13% 2019-03-31
Northern Trust Investments N A 2219101 0.09% -51706 -2.28% 2019-03-31
Northern Trust Corp 2219101 0.09% -51706 -2.28% 2019-03-31
Brandes Investment Partners & Co 2329001 0.09% -33948 -1.44% 2019-03-31
Morgan Stanley - Brokerage Accounts 2344823 0.09% 230734 10.91% 2019-03-31
Lazard Asset Management LLC 2384716 0.10% 2379716 47594.32% 2019-03-31
Amvescap Plc. 7356136 0.29% 187494 2.62% 2018-12-31
BlackRock Inc 2400209 0.10% -614138 -20.37% 2018-12-31
John Hancock Advisers, LLC 2967621 0.12% -- -- 2018-11-30
Franklin Advisers, Inc. 2401775 0.10% -18188292 -88.34% 2018-06-30
Delaware Management Business Trust 3046281 0.12% -29658 -0.96% 2018-06-30
Invesco Advisers, Inc 6075309 0.24% -256726 -4.05% 2018-06-30
Berkshire Hathaway Inc 3701012 0.15% -- -- 2018-06-30
Franklin Resources Inc 2724798 0.11% -18107782 -86.92% 2018-06-30
Wells Fargo & Co 2468987 0.10% -228800 -8.48% 2018-06-30
Managed Account Advisors LLC 3572350 0.14% -240381 -6.30% 2018-06-30
Franklin Advisers Inc 2401775 0.10% -18188292 -88.34% 2018-06-30
Federated Investment Management Company 2252536 0.09% -182844 -7.51% 2018-03-31
Wells Fargo Advisors, LLC 2113652 0.08% -204419 -8.82% 2018-06-30
Merrill Lynch & Co Inc 2066817 0.08% 228249 12.41% 2018-06-30
Raymond James & Associates 1630298 0.07% -47354 -2.82% 2018-06-30
Morgan Stanley Smith Barney LLC 1706675 0.07% -519325 -23.33% 2018-03-31
Morgan Stanley & Co International PLC 1796061 0.07% -382243 -17.55% 2018-03-31
Robeco Investment Management, Inc. 8472489 0.34% -192494 -2.22% 2017-12-31
Southpoint Capital Advisors LP 2200000 0.09% 200000 10.00% 2017-12-31
Royal Bank Of Canada 1724330 0.07% -160568 -8.52% 2017-09-30
Macquarie Investment Management Limited 2622391 0.10% 2622391 -- 2017-09-30
Capital World Investors 2185000 0.08% -- -- 2016-09-30
Harris Associates L.P. 3273405 0.13% -2298670 -41.25% 2016-09-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Hamlin High Dividend Equity Fund 579410 0.02% -13900 -2.34% 2019-03-31
Dodge & Cox Stock Fund 40337328 1.61% -- -- 2019-06-30
Vanguard Windsor 12106718 0.48% -590800 -4.65% 2019-03-31
Dodge & Cox Balanced Fund 5570265 0.22% -40000 -0.71% 2019-06-30
Invesco Comstock Fund 3740491 0.15% -- -- 2019-06-30
Bridge Builder Large Cap Value Fund 1956378 0.08% -107205 -5.20% 2019-06-30
Delaware Healthcare Fund 1350000 0.05% -- -- 2019-06-30
Fidelity 1252522 0.05% -- -- 2019-06-30
Hamlin Equity Income Strategy- UBS 1167845 0.05% -48198 -3.96% 2019-03-31
Artisan Value Equity Trust 1162743 0.05% 1162743 -- 2019-03-31
Schwab Instl Large Cap Value Tr Fd 1016744 0.04% -13028 -1.27% 2019-03-31
CREF Stock Account 583851 0.02% -- -- 2019-05-31
American Beacon Large Cap Value Fund 731205 0.03% -21826 -2.90% 2019-05-31
BlackRock Health Sciences Opps Port 778900 0.03% -- -- 2019-06-30
Invesco Health Care Fund 787572 0.03% -- -- 2019-06-30
BrighthouseI Invesco Comstock Portfolio 790678 0.03% -- -- 2019-03-31
First Trust Value Line 840875 0.03% 2508 0.30% 2019-07-31
Vanguard PrimeCap Fund 1008000 0.04% -- -- 2019-03-31
Vanguard VIF Diversified Val Portfolio 578837 0.02% -- -- 2018-12-31
Vanguard PrimeCap Core Fund 540000 0.02% -- -- 2018-12-31
DFA International Core Equity Portfolio 483567 0.02% -- -- 2018-12-31
Fidelity Advisor 481000 0.02% -- -- 2018-11-30
AST Hotchkis & Wiley Large-Cap Val Port 483900 0.02% -- -- 2018-11-30
Invesco VI Comstock Fund 492171 0.02% -12008 -2.38% 2018-09-30
TIAA-CREF Large-Cap Value 691541 0.03% -6976 -1.00% 2018-10-31
Franklin Income Fund 3025400 0.12% -14474600 -82.71% 2018-06-30
Robeco BP US Large Cap Equities 628561 0.03% 3777 0.60% 2018-01-31
Robeco BP US Premium Equities 1023858 0.04% -- -- 2018-01-31
JHancock Disciplined Value Fund 2865321 0.12% -- -- 2018-01-31
BlackRock Health Sciences Opps Inv A 943500 0.04% -- -- 2018-07-31
TIAA-CREF Large-Cap Value Instl 477569 0.02% 477569 -- 2018-07-31
DFA International Core Equity I 483567 0.02% -- -- 2018-07-31
Vanguard PRIMECAP Core Inv 540000 0.02% -- -- 2018-06-30
Dodge & Cox Stock 40619428 1.63% -- -- 2018-06-30
Dodge & Cox Balanced 6205265 0.25% -100000 -1.59% 2018-06-30
Invesco Comstock A 3871425 0.16% -56217 -1.43% 2018-06-30
American Beacon Lg Cap Value Inst 1081645 0.04% -51200 -4.52% 2018-07-31
Schwab Instl Lrg Cap Value Tr Fd-Ret 1052034 0.04% -427 -0.04% 2018-06-30
Vanguard PRIMECAP Inv 1008000 0.04% -- -- 2018-06-30
Met Invt Ser Invesco Comstock B 859119 0.03% -67280 -7.26% 2018-06-30
Hamlin High Dividend Equity Instl 607565 0.02% 54280 9.81% 2018-06-30
Vanguard VIF Diversified Val 582900 0.02% -30000 -4.89% 2018-06-30
AST Large-Cap Value 524800 0.02% -44200 -7.77% 2018-07-31
PowerShares Intl Div Achiev ETF 496892 0.02% -- -- 2018-09-13
Invesco VI Comstock II 504179 0.02% -73616 -12.74% 2018-06-30
Franklin Income A 3025400 0.12% -14474600 -82.71% 2018-06-30
JNL/Franklin Templeton Income B 610000 0.02% -- -- 2018-03-31
Franklin Income VIP 2 708292 0.03% -- -- 2018-05-31
Boston Partners Large Cap Value Equity Fund - Class G 562506 0.02% 30062 5.65% 2017-12-31
JHancock Disciplined Value I 2865321 0.11% -- -- 2018-01-31
Fidelity VIP Contrafund Inv 612500 0.02% 7700 1.27% 2017-12-31
Invesco Global Health Care A 863336 0.03% -271232 -23.91% 2016-12-31
Oakmark I 3170000 0.12% -- -- 2016-12-31
Oakmark Fund 5670000 0.20% -- -- 2015-09-30
Invesco Comstock 3685736 0.10% -- -- 2015-09-30
Fidelity® Select Pharmaceuticals Port 3141222 0.10% -61000 -1.90% 2015-09-30
Fidelity® Select Health Care Portfolio 1400000 -- -880000 -38.60% 2015-09-30
Sound Shore Fund 1356500 -- -17400 -1.30% 2015-06-30
Fidelity® Dividend Growth Fund 1269900 -- -- -- 2015-09-30
Fidelity® Equity Dividend Income 1119900 -- -- -- 2015-09-30
Franklin Income VIP Fund 1108292 -- -260000 -19.00% 2015-09-30
Invesco Global Health Care Fd 921663 -- -- -- 2015-09-30
Vanguard Windsor II Fund 18170900 0.70% -977000 -5.10% 2015-09-30

Serge Weinberg Serge Weinberg is a French businessperson who founded Institut du Cerveau et de la Moelle �0�1‰pini�0�1¨re and Weinberg Capital Partners SAS and who has been at the head of 19 different companies. Presently, he is Chairman at Maremma SASU, Chairman of Financi�0�1¨re Piasa SAS, Chairman at Piasa Holding SAS, Chairman for Sanofi, President at Weinberg Capital Partners SAS and Manager for Maremma. Mr. Weinberg is also on the board of Madrigall SA, Piasa SA (former Chairman) and AFEPT and Manager of Alret and Member of Council on Foreign Relations, Inc. In the past Mr. Weinberg was Chairman-Supervisory Board of Tess SAS, Chairman & Chief Executive Officer of Rexel SA, Chairman for Accor SA, Chairman for CORUM Verm�0�1�0�9gensverwaltung AG, Chairman-Supervisory Board of Financi�0�1¨re Tess SAS, Chairman-Supervisory Board at Financi�0�1¨re Climater SAS, Director at VL Holding (France), Chief Executive Officer & Director at Pallas Finance, Chairman-Management Board at Kering SA, President-CFAO at Pinault SARL, Manager of Adoval, Chairman for Montres CORUM S�0�1�0�2rl, Chairman & Chief Executive Officer for Havas Tourisme, President of Compagnie Fran�0�1§aise de L'Afrique Occidentale SA and Deputy General Manager-Finance at France 3 SA. Serge Weinberg received a graduate degree from Institut d'�0�1‰tudes Politiques d'Aix-en-Provence and an undergraduate degree from Ecole Nationale d'Administration.
Bernard Charl�0�1¨s Bernard Charl�0�1¨s is a French businessperson who has been at the helm of 14 different companies. Currently, he holds the position of Vice Chairman & Chief Executive Officer at Dassault Syst�0�1¨mes SA and Chairman at Dassault Systemes Geovia, Inc., Chairman of Centric Software, Inc., Chairman & Chief Executive Officer at Exa Corp., Chairman of Dassault Syst�0�1¨mes Corp., Chairman at Dassault Systemes Simulia Corp. and Chief Executive Officer & Vice Chairman at Exalead SA (which are all subsidiaries of Dassault Syst�0�1¨mes SA) and Chairman of Dassault Systemes Solidworks Corp. Bernard Charl�0�1¨s is also on the board of Sanofi and Member of National Academy of Engineering. He previously was Chairman at Dassault Syst�0�1¨mes Canada Software, Inc., Chairman-Supervisory Board for Dassault Systemes 3DExcite GmbH, Chairman of Dassault Systemes Biovia Corp., Chairman for Dassault Systemes Enovia Corp., Chairman for Delmia Corp., President of Dassault Syst�0�1¨mes Canada, Inc. and Member of Acad�0�1�0�8mie des Technologies. He received an undergraduate degree from �0�1‰cole normale sup�0�1�0�8rieure de Cachan.
John C. Reed John C. Reed founded Apoptos, Inc. and Idun Pharmaceuticals, Inc. Currently, Dr. Reed holds the position of Head-Global Research & Development at Sanofi. He is also on the board of BIOCOM. In the past he was Head-Roche Pharma Research & Early Development at Roche Holding AG, President, Chief Executive Officer & Professor at Sanford Burnham Prebys Medical Discovery Institute, Associate Member at the University of California San Diego, Assistant Director at the University of Pennsylvania and Associate Member at Whitaker Institute of Biomedical Engineering. John C. Reed received an undergraduate degree from the University of Virginia and a doctorate from Perelman School of Medicine.
Patrick Kron Mr. Patrick Kron is a Chairman at Imerys SA, an Independent Director at LafargeHolcim Ltd., an Independent Director at Sanofi and a Chairman at Pkc&I SAS. He is on the Board of Directors at ElvalHalcor Hellenic Copper & Aluminium Industry SA, LafargeHolcim Ltd., Sanofi, Bouygues SA, Gentilly Verdun SNC, Halcor Metal Works SA, Segula Technologies SA and Les Arts Florissants. Mr. Kron was previously employed as a Chairman & Chief Executive Officer by Alstom Transport SA, a Chairman & Chief Executive Officer by Alstom SA, a Chief Operating Officer by American National Can Corp, a Chairman & Chief Executive Officer by Carbone Lorraine Applications Electriques, a Chairman by Le Carbone Lorraine SA, a Chairman & Chief Executive Officer by Pechiney Electrom�0�1�0�8tallurgie SA, a Manager-Food & Health Care Packaging Sector by Pechiney SA, a Chief Executive Officer & Director by Alstom Asia Pacific Sdn. Bhd., a Managing Director & Director by Alstom Asia Pte Ltd., a Chairman by ALSTOM Resources Management SAS, and a Chief Executive Officer by Vivendi SA. He also served on the board at ALSTOM UK Holdings Ltd. and Association Fran�0�1§aise des Entreprises Priv�0�1�0�8es. He received his undergraduate degree from Ecole Polytechnique and an undergraduate degree from �0�1‰cole Nationale Sup�0�1�0�8rieure des Mines de Paris.
J�0�1�0�8r�0�1�0�7me Contamine Currently, J�0�1�0�8r�0�1�0�7me Contamine is President of Sanofi 1 and Chief Financial Officer & Executive VP-Finance at Sanofi, Chairman at Secipe SA, Chief Executive Officer at Sanofi-Aventis Participations SAS, Chief Executive Officer of Sanofi-Aventis Europe SAS, Chief Financial Officer & Executive Vice President for Sanofi-Aventis U.S. LLC and Manager of Sanofi 4 (which are all subsidiaries of Sanofi). J�0�1�0�8r�0�1�0�7me Contamine is also on the board of Soci�0�1�0�8t�0�1�0�8 G�0�1�0�8n�0�1�0�8rale SA and Sanofi Pasteur Holding SA and Manager at Sanofi 4. In the past Mr. Contamine was Vice President-Finance at Veolia Environnement SA, Chief Financial Officer for Rhodia SA and Vice President for Total E&P Norge AS. He received an undergraduate degree from Ecole Polytechnique, an undergraduate degree from Ecole Nationale de la Statistique & de l'Administration and an undergraduate degree from Ecole Nationale d'Administration.
Alan J. Main Alan J. Main is Executive Vice President-CMC & Supply Operations at Lexicon Pharmaceuticals, Inc. He previously held the position of President & Chief Executive Officer of Coelacanth Corp and Senior Vice President-US Research at Novartis Pharmaceuticals Corp. Alan J. Main received an undergraduate degree from the University of Aberdeen and a doctorate from The University of Liverpool.
George Grofik Currently, George Grofik occupies the position of Head-Investor Relations for Sanofi. In his past career he was Research Analyst at Citigroup Global Markets, Inc. (Broker).
Muzammil M. Mansuri Currently, Muzammil M. Mansuri is Executive Chairman at Adaptive Therapeutics, Inc. Dr. Mansuri is also Executive VP-Strategy & Business Development at Sanofi. In his past career Dr. Mansuri occupied the position of General Partner at Flagship Pioneering, SVP-Research & Development Strategy at Gilead Sciences, Inc. and Chairman & Chief Executive Officer at Gilead Connecticut, Inc. (a subsidiary of Gilead Sciences, Inc.), Director-Central Chemistry at Bristol-Myers Squibb Co., Senior Advisor at JSB-Partners LP, Chief Operating Officer & Executive Vice President of GPC Biotech, Inc., President & Chief Executive Officer at BIKAM Pharmaceuticals, Inc. and Research Scientist at Shell Research Ltd. Dr. Mansuri received a doctorate and an undergraduate degree from University College London, a doctorate from the University of California, Los Angeles and a doctorate from Columbia University.
Carole Piwnica Ms. Carole Piwnica is Member-Supervisory Board at Rothschild & Co. SCA, Chairman at i2O Water Ltd., Independent Director at Sanofi, Independent Director at Eutelsat Communications SA, Independent Director at Amyris, Inc., a Director at Select Music & Video Distribution Ltd., a Managing Director at Naxos UK Ltd., a Managing Director at NAXOS Capital Managers SARL, a Member at New York State Bar Association and a Member at Paris Bar Association. She is on the Board of Directors at Rothschild & Co. SCA, Sanofi, Elevance Renewable Sciences, Inc., Eutelsat Communications SA, Amyris, Inc., Big Red, Inc., Select Music & Video Distribution Ltd. and RecyCoal Ltd. Ms. Piwnica was previously employed as Independent Director by Louis Delhaize SA, Independent Non-Executive Director by Aviva Plc, Non-Executive Director by SPADEL SA, a Director & Vice Chairman-Governmental Affairs by Tate & Lyle Plc, and Chairman by Amylum. She also served on the board at BioAmber, Inc., Confederation of the Food & Drink Industries of Eu, Alfred C. Toepfer International GmbH, Charal SAS, Cacao Barry, and TargeGen, Inc. Ms. Piwnica received her graduate degree from Universit�0�1�0�8 Libre de Bruxelles and a graduate degree from New York University.
Christian Mulliez Currently, Christian Mulliez is Chief Financial Officer & EVP-Administration at L'Or�0�1�0�8al SA and Chairman for Banque de R�0�1�0�8alisations de Gestion et de Financement (a subsidiary of L'Or�0�1�0�8al SA). He is also on the board of Sanofi and Dg 17 Invest. In his past career he held the position of Vice President-Finance at Sanofi-Synth�0�1�0�8labo SA and Vice President-Finance of Synth�0�1�0�8labo SA. Christian Mulliez received an undergraduate degree from ESSEC Business School.
Melanie Georgina Lee Founder of Think10 and NightstaRx Ltd., Melanie Georgina Lee is on the board of Sanofi and Chief Executive Officer at Lifearc. In her past career Dr. Lee was Chief Executive Officer at Ipsen Bioinnovation Ltd., Chief Scientific Officer for BTG Plc, Chairman at Cancer Research Technology Ltd., Chief Executive Officer for NightstaRx Ltd., Executive Vice President-Research & Development at UCB Pharma, Inc., Director-Research & Development at Celltech Group Ltd., Research Unit Head-Receptor Systems at GlaxoWellcome, Principal at GlaxoSmithKline Pharmaceuticals SA (Belgium), President-New Medicines at UCB Celltech and Director at Think10. Dr. Lee received an undergraduate degree from York University.
Olivier Brandicourt Olivier Brandicourt is a French businessperson who has been at the helm of 6 different companies. He occupies the position of Chief Executive Officer & Director at Sanofi and Chairman for Sanofi Biotechnology SAS (a subsidiary of Sanofi). He is also on the board of National Committee on United States-China Relations, Inc. and Chairman of Pharmaceutical Research & Manufacturers of America, Vice President & Member at European Federation of Pharmaceutical Industries & Assns and Council Member at International Federation of Pharmaceutical Manufacturers. He previously held the position of President & General Manager-Emerging Markets at Pfizer Inc. Managing Director at Pfizer Ltd. Managing Director at Pfizer Manufacturing Ireland Unlimited Co. Vice President at Warner-Lambert Co. and Vice President & General Manager at Parke, Davis & Co. LLC (which are all subsidiaries of Pfizer Inc.) and Executive Council Member at Bayer AG and Chairman-Management Board at Bayer HealthCare AG (a subsidiary of Bayer AG). He received a doctorate and a graduate degree from Universit�0�1�0�8 Paris XII and an undergraduate degree from the University of Paris V.
Elias A. Zerhouni Dr. Elias A. Zerhouni, MD, is a President-Global Research & Development at Sanofi, a Member at Acad�0�1�0�8mie Nationale de M�0�1�0�8decine, an Independent Director at Danaher Corp., a Member at National Academy of Engineering, a Member at Institute of Medicine and a Professor at The Johns Hopkins University. He is on the Board of Directors at Danaher Corp., Research!America, Warp Drive Bio LLC and King Abdullah University of Science & Technology. Dr. Zerhouni was previously employed as a Trustee-Emeritus by The Mayo Clinic, a Chairman & President by The Zerhouni Group LLC, a Chairman-Innovation by College de France, a Trustee by Lasker Foundation, and a Chairman-Russell H. Morgan Department by The Johns Hopkins Health System Corp. He also served on the board at Actelion Ltd., National Institutes of Health and Mayo Medical Ventures. He received his doctorate degree from The University of Algiers.
Laurent Attal Currently, Laurent Attal holds the position of Vice President & GM-Research & Innovation at L'Or�0�1�0�8al SA. Dr. Attal is also on the board of Sanofi and L'Or�0�1�0�8al Corporate Foundation. In his past career Dr. Attal was Chief Executive Officer of Vichy, President & Chief Executive Officer of L'Or�0�1�0�8al USA, Inc. and Manager at Galderma SA. Dr. Attal received an MBA from INSEAD.
Robert Castaigne Dr. Robert Castaigne is an Independent Director at NOVATEK JSC, an Independent Non-Executive Director at Soci�0�1�0�8t�0�1�0�8 G�0�1�0�8n�0�1�0�8rale SA, an Independent Director at VINCI SA and an Independent Director at Sanofi. He is on the Board of Directors at NOVATEK JSC, Soci�0�1�0�8t�0�1�0�8 G�0�1�0�8n�0�1�0�8rale SA, VINCI SA, Sanofi, Omnium Insurance & Reinsurance Co. Ltd., Total Gestion Filiales and Total Upstream UK Ltd. Dr. Castaigne was previously employed as an Independent Non-Executive Director by Cie Nationale �0�1�0�2 Portefeuille SA /OLD/, an Independent Director by Sanofi, a Chairman & Chief Executive Officer by Total Chimie SA, and a Chief Financial Officer by Total SA. He also served on the board at Total Gabon, Arkema SA, Elf Aquitaine SA, Hutchinson SA, NPM-CNP, Petrofina SA and Total Nucleaire. He received his undergraduate degree from �0�1‰cole centrale de Lille, an undergraduate degree from IFP School and a doctorate degree from Universit�0�1�0�8 Paris 1.
Claudie Haigner�0�1�0�8 Claudie Haigner�0�1�0�8 is Member of Academie de l'air et de l'espace, Member of Acad�0�1�0�8mie des Sciences et Technologies, Member of Acad�0�1�0�8mie Des Sciences D'Outre-Mer and Member of Academie des Sports and on the board of 6 other companies. In the past she was Chairman at Universcience.fr, Chairman for La G�0�1�0�8ode, Counselor at European Space Agency, Member of International Academy of Astronautics and Member of Acad�0�1�0�8mie des Technologies.
Karen Linehan Currently, Karen Linehan holds the position of Executive VP-Legal Affairs & General Counsel at Sanofi. Ms. Linehan received a graduate degree and an undergraduate degree from Georgetown University.
Suet-Fern Lee Suet-Fern Lee founded Stamford Law Corp. Ms. Lee is Partner at Morgan Lewis Stamford LLC. She is also Member of The Bar Council, Chairman-Legal Education & Studies Committee at Singapore Academy of Law, Member of Singapore Bar and Member of International Bar Association and on the board of 10 other companies. In the past she was Senior Partner at Stamford Law Corp., President at Inter-Pacific Bar Association, Director & Member at National Heritage Board, Chairman of Asian Civilisations Museum and Member of The Honourable Society of Gray's Inn. She received a graduate degree from the University of Cambridge.
Emmanuel Andre Marie Babeau Currently, Emmanuel Andre Marie Babeau occupies the position of Deputy Chief Executive Officer-Finance & Legal at Schneider Electric SE. He is also Managing Partner at Sci Getij and on the board of 16 other companies. In the past Mr. Babeau occupied the position of Deputy Chief Executive Officer for Pernod Ricard SA, Chairman & Member-Management Board at Schneider Electric Services International, Chief Financial Officer at Schneider Electric Ltd. and Member-Management Board at Schneider SA. He received an undergraduate degree from ESCP Europe Campus Paris.
Karen Linehan Currently, Karen Linehan holds the position of Executive VP-Legal Affairs & General Counsel at Sanofi. Ms. Linehan received a graduate degree and an undergraduate degree from Georgetown University.
Philippe Luscan Philippe Luscan is Executive Vice President-Global Industrial Affairs at Sanofi. In his past career Mr. Luscan held the position of Production Manager at Danone SA. Mr. Luscan received an undergraduate degree from Ecole Polytechnique and an undergraduate degree from �0�1‰cole Nationale Sup�0�1�0�8rieure des Mines de Paris.
Olivier Antoine M. Charmeil Olivier Antoine M. Charmeil is EVP-General Medicines & Emerging Markets at Sanofi. In the past Mr. Charmeil occupied the position of Chairman-Management Board at Zentiva Group as, Chairman & Chief Executive Officer of Sanofi-Synth�0�1�0�8labo SA and Head-Business Development at Sanofi Pharma. Mr. Charmeil received an undergraduate degree from Sciences Po and an undergraduate degree from �0�1‰cole des Hautes �0�1‰tudes Commerciales de Paris.
Fabienne Lecorvaisier Currently, Fabienne Lecorvaisier holds the position of Chief Financial Officer & Vice President at Air Liquide SA and Chairman & Chief Executive Officer at Air Liquide Finance SA and Executive Vice President at Air Liquide International Corp. (both are subsidiaries of Air Liquide SA). Fabienne Lecorvaisier is also Executive Vice President for Air Liquide International Corp. and on the board of 6 other companies. In the past she occupied the position of Chief Financial Officer of Essilor Group Canada, Inc., Vice President-Operations & Finance at Air Liquide Italia SpA, Director-Finance & Information Systems at Essilor of America, Inc., Assistant General Manager at Taittinger SAS and Assistant General Manager at Banque du Louvre. She received an undergraduate degree from Ecole Nationale des Ponts et Chauss�0�1�0�8es.
Thomas C. S�0�1�0�4dhof Founder of Reata Pharmaceuticals, Inc., Neucyte, Inc. and Circuit Therapeutics, Inc., Thomas C. S�0�1�0�4dhof is an entrepreneur is on the board of Sanofi and Abide Therapeutics, Inc. and Professor at Stanford University School of Medicine. In the past he was Assistant Professor at The University of Texas Southwestern Medical Center. He received a doctorate from RWTH Aachen University and an undergraduate degree from the University of Gottingen.
Jean-Baptiste Chasseloup de Chatillon Jean-Baptiste Chasseloup de Chatillon is a French businessperson who has been at the helm of 5 different companies. Currently, he occupies the position of Chief Financial Officer & Executive Vice President for Sanofi, Chairman for Mister-Auto SAS and Vice Chairman & Chief Executive Officer of PSA International SA. He is also Chief Financial & Information Officer at Fondation PSA Peugeot Citro�0�1�0�0n, Member of City on the Move Institute and Associate Manager at Peugeot Media Production and on the board of 12 other companies. In his past career Mr. Chasseloup de Chatillon held the position of Chairman for Asm Auto Sud Marche SAS and CFO & Executive VP-Strategic Development at Peugeot SA Director at Banque PSA Finance SA, Chairman-Supervisory Board of Peugeot Finance International NV and Managing Director at Citro�0�1�0�0n BELUX SA (which are all subsidiaries of Peugeot SA). He received an undergraduate degree from Universit�0�1�0�8 Paris Dauphine and an undergraduate degree from the University of Lancaster.
Dominique Carouge Dominique Carouge holds the position of Executive VP & Head-Business Transformation at Sanofi. In his past career Mr. Carouge was Chief Financial Officer for Hoechst Marion Roussel Australia Pty Ltd. Mr. Carouge received an undergraduate degree from Reims Management School.
Caroline Luscombe Presently, Caroline Luscombe is Executive Vice President-Human Resources at Sanofi. In the past Ms. Luscombe was Head-Organization & Human Resources at LafargeHolcim Ltd., Executive Vice President-Human Resources of Amersham Plc and Head-Human Resources at Syngenta AG. She received an undergraduate degree from University College London.
Muzammil M. Mansuri Currently, Muzammil M. Mansuri is Executive Chairman at Adaptive Therapeutics, Inc. Dr. Mansuri is also Executive VP-Strategy & Business Development at Sanofi. In his past career Dr. Mansuri occupied the position of General Partner at Flagship Pioneering, SVP-Research & Development Strategy at Gilead Sciences, Inc. and Chairman & Chief Executive Officer at Gilead Connecticut, Inc. (a subsidiary of Gilead Sciences, Inc.), Director-Central Chemistry at Bristol-Myers Squibb Co., Senior Advisor at JSB-Partners LP, Chief Operating Officer & Executive Vice President of GPC Biotech, Inc., President & Chief Executive Officer at BIKAM Pharmaceuticals, Inc. and Research Scientist at Shell Research Ltd. Dr. Mansuri received a doctorate and an undergraduate degree from University College London, a doctorate from the University of California, Los Angeles and a doctorate from Columbia University.
Claire Massiot-Jouault Ms. Claire Massiot-Jouault is Head-Operational Excellence & Lean Manufacturing at Sanofi and General Manager at La Residence de la Ferme De Croisil. She is on the Board of Directors at Guerbet SA. She received her graduate degree from Universit�0�1�0�8 Pierre et Marie Curie and a doctorate degree from the University of Paris V.
Ameet Nathwani Ameet Nathwani occupies the position of Chief Medical & Digital Officer at Sanofi. He previously occupied the position of Global Head-Medical Affairs at Novartis Pharma AG and Head-Critical Care at Novartis Pharma AG.
Muzammil M. Mansuri Currently, Muzammil M. Mansuri is Executive Chairman at Adaptive Therapeutics, Inc. Dr. Mansuri is also Executive VP-Strategy & Business Development at Sanofi. In his past career Dr. Mansuri occupied the position of General Partner at Flagship Pioneering, SVP-Research & Development Strategy at Gilead Sciences, Inc. and Chairman & Chief Executive Officer at Gilead Connecticut, Inc. (a subsidiary of Gilead Sciences, Inc.), Director-Central Chemistry at Bristol-Myers Squibb Co., Senior Advisor at JSB-Partners LP, Chief Operating Officer & Executive Vice President of GPC Biotech, Inc., President & Chief Executive Officer at BIKAM Pharmaceuticals, Inc. and Research Scientist at Shell Research Ltd. Dr. Mansuri received a doctorate and an undergraduate degree from University College London, a doctorate from the University of California, Los Angeles and a doctorate from Columbia University.
Diane D. Souza Diane D. Souza is on the board of Sanofi, Farm Credit East, ACA and DBP Services of New York IPA, Inc. In the past he held the position of Chief Executive Officer-Specialty Benefits at UnitedHealth Group, Inc. Chief Executive Officer of UnitedHealthcare Specialty Benefits LLC and COO-OptumHealth Specialty Benefits at OptumHealth, Inc. (both are subsidiaries of UnitedHealth Group, Inc.) and CFO-Guaranteed Products Business at Aetna, Inc. He received an undergraduate degree from the University of Massachusetts.
Bill Sibold Bill Sibold is on the board of Biotechnology Innovation Organization and Executive Vice President-Sanofi Genzyme at Sanofi.
Stefan Oelrich Stefan Oelrich is Executive VP-Diabetes & Cardiovascular at Sanofi and Head-Pharmaceuticals Division at Bayer AG.
Marion Palme Marion Palme is on the board of Sanofi and Member of Industriegewerkschaft Bergbau Chemie Energie. She previously held the position of Member of European Works Council. Ms. Palme received an undergraduate degree from Provadis School of International Management & Technology.
Christian Senectaire Christian Senectaire is on the board of Sanofi.
Klaus Henning Jensen Klaus Henning Jensen is Therapeutic Area Head & Diabetes Development at Sanofi.
Nestle Frank Nestle Frank is Global Head-Immunology Therapeutic Research Area at Sanofi.
Joanne Lager Joanne Lager is Vice President & Head-Development at Sanofi.
Christophe Babule Presently, Christophe Babule is Chief Financial Officer & Executive Vice President at L'Or�0�1�0�8al SA. Mr. Babule is also on the board of Sanofi. Mr. Babule received an undergraduate degree from �0�1‰cole des Hautes �0�1‰tudes Commerciales de Paris.
Alan Main Alan Main is Executive Vice President-Consumer Health Care at Sanofi. In the past Mr. Main held the position of Marketing Manager at Roche Enterprises Ltd. and Chairman-Marketing Council at Bayer HealthCare AG. He received an undergraduate degree from the University of Greenwich.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐